CVKD
NASDAQ HealthcareCadrenal Therapeutics, Inc. - Common Stock
Biotechnology
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
๐ Market Data
| Price | $6.35 |
|---|---|
| Volume | 127,576 |
| Market Cap | 19.55M |
| Beta | 1.550 |
| RSI (14-Day) | 67.6 |
| 200-Day MA | $9.60 |
| 50-Day MA | $6.28 |
| 52-Week High | $17.00 |
| 52-Week Low | $4.21 |
| Forward P/E | -1.62 |
| Price / Book | 5.42 |
๐ฏ Investment Strategy Scores
CVKD scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (90/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (12/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find CVKD in your text
Paste any article, transcript, or post โ the tool will extract CVKD and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.